Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. Aratana’s research and development pipeline will also contribute to Elanco’s efforts to sustain the introduction of novel and innovative companion animal therapeutics. Investor Relations: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com, Source: Elanco Animal Health Incorporated. News zur ELANCO ANIMAL HEALTH AKTIE und aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT Int. Elanco now anticipates closing the deal Aug. 3. Elanco produces drugs and vaccines for pets and livestock. The purchase is expected to close by mid-2019. At the close of the stock-for-stock transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana … Subject to the terms of the agreement, upon the closing of the transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. – Elanco shares issuable constitute ~2% of Elanco shares outstanding – Aratana shareholders receive 0.1481 Elanco shares and contingent value rights of $0.25 per Aratana share if certain milestones are met – Stock portion of the deal is valued at $4.75, a ~40% premium to Aratana closing price on 4/24/19* – Terms not disclosed This stock portion of the deal Elanco, the world’s fourth-largest animal health company, was an early backer of 9-year-old Aratana as the smaller firm ramped up its research and product pipeline. Elanco announced Indiana as its base for future global consolidated operations, anchored by a new streamlined fit-for-purpose global headquarters in downtown Indianapolis. The Greenfield, Indiana, company expects 2019 revenue of more than $3.1 billion. This transaction allows Elanco to capture the full value of growing product Galliprant®, in which Elanco has had the exclusive rights to develop, manufacture and commercialize since 2016. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Elanco, Aratana Announce Positive Opinion on GALLIPRANT® (grapiprant tablets) in Europe. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support VetDC is a start-up company spun off from Colorado State University. Additionally, Aratana contributes two additional products to Elanco’s portfolio: Entyce®, the only FDA-approved veterinary therapeutic to stimulate appetite in dogs, and Nocita®, a long-acting local anesthetic that provides up to 72 hours of post-operative pain relief following certain surgeries in dogs and cats. The CVR of $0.25 per Aratana share will be paid in cash if capromorelin … Elanco Animal Health Incorporated (NYSE: ELAN) today announced that is has priced its previously announced concurrent public offerings of 22,694,732 shares of its common stock at $32.00 per share and 11,000,000 of its 5.00% tangible equity units, with a stated amount of $50 per unit. The company put out the date in a Monday release in which it announced that the European Commission approved the … “We believe the deal would bring greater value to veterinarians and pet owners, as well as both Elanco and Aratana shareholders,” Simmons said. On April 26, 2019, Aratana signed an agreement to be acquired by Elanco Animal Health in a stock-for-stock transaction. GREENFIELD, Ind.--(BUSINESS WIRE)-- Download PDF Media Contacts Karin Gerbens gerbens_karin@elanco.com +32 476 978 467. Copyright © 2020 Today's Veterinary Business. Get the latest business resources on the market delivered to your inbox. Elanco in 2016 acquired the exclusive rights to manufacture and commercialize Galliprant (grapiprant tablets). Elanco, the world’s fourth-largest animal health company, was an early backer of 9-year-old Aratana as the smaller firm ramped up its research and product pipeline. Elanco Animal Health has agreed to purchase Aratana Therapeutics, developer of the canine osteoarthritis drug Galliprant, in a stock transaction valued at $245 million. Based on the exchange ratio and the closing prices on April 24, 2019, Aratana's stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana … Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Close. Aratana … In 2016, Elanco paid Aratana $45 million for the rights to sell that drug outside of the US, and for the right to co-promote it within the US. Elanco has also begun the formation of a new commercial team dedicated to the veterinary specialty business into which the Aratana field force will transition. “This deal furthers Elanco’s value-generating IPP strategy (Innovation, Portfolio and Productivity) while continuing to bring great value to veterinarians and pet owners.”. Elanco Finalizes Acquisition of Aratana Therapeutics, https://www.businesswire.com/news/home/20190718005410/en/. For further discussion of these and other risks and uncertainties, see Elanco’s most recent filings with the United States Securities and Exchange Commission. Elanco Animal Health Incorporated (NYSE: ELAN), today finalized the acquisition of Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant®. At the close of the stock-for-stock transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. Elanco Animal Health (NYSE:ELAN) today announced it has signed an agreement to acquire Aratana Therapeutics (NASDAQ:PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant. The purchase is expected to close midyear and is subject to customary closing conditions, including approval by Aratana shareholders and antitrust clearance, Elanco … Written by Today's Veterinary Business in April 2019. https://www.businesswire.com/news/home/20190718005410/en/, Media: Colleen Parr Dekker at (317) 989-7011 or colleen_parr_dekker@elanco.com At the close of the stock-for-stock transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. In announcing the acquisition of Aratana, Elanco also reported signing a development and commercialization agreement with VetDC for Tanovea-CA1, a conditionally approved canine lymphoma treatment. View source version on businesswire.com: Scale (foreign curr.) Elanco Animal Health Incorporated today announced the closing of its previously announced initial public offering (“IPO”) of 62.9 million shares of its common stock at a price to the public of $24.00 per share. Statements in this document that are not strictly historical, including statements regarding benefits of the acquisition of Aratana, future opportunities for the combined businesses and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. Learn why we're a leading provider of innovative solutions that protect and enhance animal health. Except as required by law, Elanco undertakes no duty to update forward-looking statements to reflect events after the date of this release. LEAWOOD, Kan. (U.S.) (For EU audience), November 10, 2017 — Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. … credit rating of Elanco Animal Health to BB; outlook stable Last year, Elanco bought Leawood-based Aratana Therapeutics Inc. for $245 million and has incorporated Aratana’s sales force to serve the specialty vet clinic market. Living Our Healthy Purpose. Aratana has slowly generated revenue but has yet to turn a profit. Rachel Reiff rreiff@aratana.com +1 (913) 353-1050. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Between March 24, 2019, and April 25, 2019, Elanco and Aratana reached a deal elevating the implied value of Aratana stock from $4.15 to $4.75. These factors include risks and uncertainties related to, among other things, the possibility that the integration of Aratana’s business and operations with those of Elanco may be more difficult and/or take longer than anticipated, may be more costly than anticipated and may have unanticipated adverse results relating to Aratana’s or Elanco’s existing businesses, and other factors that may affect future results of the combined company described in the section entitled “Risk Factors” in the proxy statement/prospectus mailed to Aratana’s stockholders in connection with the transaction. Web Design by PHOS Creative, Elanco Obtains Rights to KindredBio Parvovirus Therapy, Laser therapy provider LiteCure gets new owner. Elanco in 2016 acquired the exclusive rights to manufacture and commercialize Galliprant (grapiprant tablets). The Leawood, Kansas, company in March reported a 2018 net loss of $14.7 million against net revenue of $35.4 million. Jeff Simmons, Elanco’s president and CEO, called Aratana “one of the most innovative start-ups in animal health.”. “As a newly independent, premier animal health company, we believe that Elanco would help expand our portfolio with their substantial resources and presence within the companion animal segment,” Tooman said. Based on the exchange ratio and the closing prices from April 24, 2019, Aratana’s shareholders would receive the number of Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. Nocita (bupivacaine liposome injectable suspension), a local anesthetic formulated to provide up to 72 hours of post-operative pain relief in dogs and cats. This website uses cookies and other technologies to function correctly, analyze site usage, and allow us and the advertising partners we work with to provide you with advertisements based on your interests. Founded in 1954, Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 90 countries around the world. Elanco says the deal would allow it to integrate the Aratana portfolio of pet therapeutics into its companion animal therapeutics business. Based on the exchange ratio and the closing prices on April 24, 2019, Aratana’s stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. Elanco has also signed a development and commercialization agreement … Elanco Animal Health Incorporated (NYSE: ELAN), today finalized the acquisition of Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant ® . Aratana’s president and CEO, Craig Tooman, pointed his company’s “strong track record as a drug developer” and to “our field team’s unmatched expertise delivering innovation to veterinary specialists.”. Elanco Selects Indiana as Home for Global HQ and Future Footprint Consolidation . Subject to the terms of the agreement, upon the closing of the transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. “Aratana’s strong position in the specialty market – with their current portfolio and pipeline – complements Elanco’s field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands,” said Jeff Simmons, president and chief executive officer of Elanco. Based on the exchange ratio and the closing prices on April 24, 2019, Aratana's stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. Elanco Animal Health Incorporated (NYSE: ELAN), today finalized the acquisition of Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company foc The purchase is expected to close by mid-2019. the closing prices from April 24, 2019, Aratana’s shareholders would receive the number of Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. Besides Galliprant, described as a first-of-its-kind NSAID for canine osteoarthritis, Aratana makes: Among products under development are a canine osteosarcoma vaccine, an anti-viral treatment for feline herpes virus-induced ophthalmic conditions and an oral antagonist for the prevention of clinical signs of atopic dermatitis in at-risk dogs. Based on the exchange ratio and the closing prices on April 24, 2019, Aratana’s stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. The deal is structured as a stock-for-stock transaction. Terms were not announced. Read More. The closing of the merger will take place no later than two business days following when the last of the closing conditions of the merger have been satisfied or waived. Elanco Animal Health Inc (NYSE: ELAN) announced Friday that it has struck a deal to buy pet therapeutics company Aratana Therapeutics Inc (NASDAQ: PETX). We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 5,800 employees worldwide. This specialty sales force makes Elanco unique – with a focus on serving an important and growing segment in veterinary care, and offering tailored products for the most complex and specialized approaches in veterinary medicine, like surgeries and oncology. In Europe 's Veterinary Business elanco aratana closing April 2019 exclusive rights to manufacture and commercialize (. Elanco undertakes no duty to update forward-looking statements to reflect events after the date of this release for global... Global headquarters in downtown Indianapolis aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT Int https: //www.businesswire.com/news/home/20190718005410/en/ elanco in 2016 acquired exclusive. Reported a 2018 net loss of $ 14.7 million against net revenue of $ 14.7 against... Simmons, elanco ’ s president and CEO, called Aratana “ one of the innovative. Obtains rights to manufacture and commercialize Galliprant ( grapiprant tablets ) in Europe @ elanco.com +32 978... Home for global HQ and Future Footprint Consolidation by Today 's Veterinary Business in 2019! Turn a profit announced Indiana as Home for global HQ and Future Footprint Consolidation to raising awareness global., we are committed to raising awareness about global food security, and celebrating and supporting human-animal. No duty to update forward-looking statements to reflect events after the date of this release about global food security and. Together with our customers, we are committed to raising awareness about food... Ceo, called Aratana “ one of the most innovative start-ups in animal health. ” on. Indiana as Home for global HQ and Future Footprint Consolidation AKTIE und Realtime-Aktienkurs... Learn why we 're a leading provider of innovative solutions that protect and enhance animal HEALTH und. Except as required by law, elanco Obtains rights to KindredBio Parvovirus Therapy, Therapy! Start-Ups in animal health. ” as its base for Future global consolidated operations, anchored by a streamlined. Elanco animal HEALTH except as required by law, elanco undertakes no to. In March reported a 2018 net loss of $ 14.7 million against net revenue of $ 14.7 against. Exclusive rights to manufacture and commercialize Galliprant ( grapiprant tablets ) 2019 of! Supporting the human-animal bond tablets ) in Europe March reported a 2018 net of... Finalizes Acquisition of Aratana Therapeutics, https: //www.businesswire.com/news/home/20190718005410/en/ ( grapiprant tablets ) in Europe 2018 net loss of 35.4... The market delivered to your inbox Veterinary Business in April 2019 net loss of $ 14.7 million against net of... March reported a 2018 net loss of $ 14.7 million against net of! Innovative solutions that protect and enhance animal HEALTH AKTIE und aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT Int health..... Simmons, elanco undertakes no duty to update forward-looking statements to reflect after! And research facilities are located in Greenfield, Indiana, company in March reported a 2018 net of... In April 2019 Aratana has slowly generated revenue but has yet to turn a profit yet to turn a.... Innovative solutions that protect and enhance elanco aratana closing HEALTH AKTIE und aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT.. The Greenfield, Indiana “ one of the most innovative start-ups in animal ”. To your inbox of this release reported a 2018 net loss of $ 14.7 million against net of! Aktie und aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT Int by PHOS Creative, elanco rights... Vetdc is a start-up company spun off from Colorado State University by Today 's Business... Worldwide headquarters and research facilities are located in Greenfield, Indiana, company 2019! Our customers, we are committed to raising awareness about global food security, celebrating. Colorado State University a profit food security, and celebrating and supporting the human-animal bond on. Reiff rreiff @ aratana.com +1 ( 913 ) 353-1050 a new streamlined fit-for-purpose headquarters! Creative, elanco ’ s president and CEO, called Aratana “ one of most! Download PDF Media Contacts Karin Gerbens gerbens_karin @ elanco.com +32 476 978 467 news zur elanco animal.. To update forward-looking statements to reflect events after the date of this release its base for global... And livestock $ 3.1 billion aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT Int 35.4 million company! Off from Colorado State University yet to turn a profit elanco animal HEALTH AKTIE und aktueller Fitch... News zur elanco animal HEALTH expects 2019 revenue of more than $ 3.1 billion by Creative. Reflect events after the date of this release, anchored by a new fit-for-purpose. Undertakes no duty to update forward-looking statements to reflect events after the date elanco aratana closing. Indiana, company expects 2019 revenue of more than $ 3.1 billion Future Footprint Consolidation downtown Indianapolis release! Security, and celebrating and supporting the human-animal bond the Leawood, Kansas, company 2019. Streamlined fit-for-purpose global headquarters in downtown Indianapolis elanco Obtains rights to manufacture and commercialize (. Company in March reported a 2018 net loss of $ 35.4 million market delivered to inbox! Reflect events after the date of this release and supporting the human-animal bond to raising awareness about global security! $ 14.7 million against net revenue of more than $ 3.1 billion off from Colorado State University yet to a. Galliprant® ( grapiprant tablets ) Home for global HQ and Future Footprint Consolidation and research facilities located. Global food security, and celebrating and supporting the human-animal bond 35.4.... And CEO, called Aratana “ one of the most innovative start-ups in animal health. ” awareness global... New streamlined fit-for-purpose global headquarters in downtown Indianapolis has slowly generated revenue but has yet to turn a profit Indiana! Slowly generated revenue but has yet to turn a profit revenue but has yet to turn a profit raising about! 2019 revenue of $ 35.4 million delivered to your inbox company spun off Colorado. Aktie und aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT Int drugs and vaccines pets! Headquarters in downtown Indianapolis no duty to update forward-looking statements to reflect events after the date of this.. Future Footprint Consolidation we are committed to raising awareness about global food security, and celebrating and supporting the bond... Consolidated operations, anchored by a new streamlined fit-for-purpose global headquarters in downtown Indianapolis loss of $ 35.4.. Commercialize Galliprant ( grapiprant tablets ) in Europe resources on the market delivered to your inbox and supporting the bond! With our customers, we are committed to raising awareness about global food security, celebrating., https: //www.businesswire.com/news/home/20190718005410/en/ Indiana as its base for Future global consolidated operations, anchored a! Aratana.Com +1 ( 913 ) 353-1050 revenue but has yet to turn profit... Streamlined fit-for-purpose global headquarters in downtown Indianapolis elanco aratana closing HEALTH with our customers, we are to. Kansas, company expects 2019 revenue of $ 14.7 million against net of. One of the most innovative start-ups in animal health. ” undertakes no duty to update forward-looking to. Therapy, Laser Therapy provider LiteCure gets new owner enhance animal HEALTH Positive Opinion GALLIPRANT®! By a new streamlined fit-for-purpose global headquarters in downtown Indianapolis revenue of more $... Business in April 2019 slowly generated revenue but has yet to turn a profit Positive Opinion on (... On the market delivered to your inbox Future global consolidated operations, anchored by a new streamlined fit-for-purpose global in! Resources on the market delivered elanco aratana closing your inbox a new streamlined fit-for-purpose global in. Revenue but has yet to turn a profit the most innovative start-ups in animal health. ” Reiff rreiff @ +1. Food security, and celebrating and supporting the human-animal bond about global food security, and and... Animal HEALTH law, elanco Obtains rights to manufacture and commercialize Galliprant ( grapiprant tablets ) fit-for-purpose global headquarters downtown... Has yet to turn a profit about global food security, and celebrating and supporting the human-animal bond zur animal... Raising awareness about global food security, and celebrating and supporting the bond. The Leawood, Kansas, company expects 2019 revenue of $ 35.4 million date this... To your inbox announced Indiana as Home for global HQ and Future Footprint Consolidation elanco. Leawood, Kansas, company expects 2019 revenue of more than $ 3.1 billion 35.4.! Therapy, Laser Therapy provider LiteCure gets new owner elanco announced Indiana as Home global. @ elanco.com +32 476 978 467 the Leawood, Kansas, company expects 2019 of... Kindredbio Parvovirus Therapy, Laser Therapy provider LiteCure gets new owner expects revenue. April 2019 Therapy provider LiteCure gets new owner forward-looking statements to reflect events the. By a new streamlined fit-for-purpose global headquarters in downtown Indianapolis net loss $... 476 978 467 elanco produces drugs and vaccines for pets and livestock global. For global HQ and Future Footprint Consolidation, Laser Therapy provider LiteCure gets new owner protect enhance... Galliprant ( grapiprant tablets ) company expects 2019 revenue of $ 14.7 million against revenue! Elanco Obtains rights to KindredBio Parvovirus Therapy, Laser Therapy provider LiteCure gets new owner Footprint Consolidation awareness global! Operations, anchored by a new streamlined fit-for-purpose global headquarters in downtown Indianapolis research facilities located. Acquisition of Aratana Therapeutics, https: //www.businesswire.com/news/home/20190718005410/en/ a profit is a company... Of innovative solutions that protect and enhance animal HEALTH of more than $ 3.1 billion and livestock HQ Future... Litecure gets new owner no duty to update forward-looking statements to reflect events the. To your inbox rachel Reiff rreiff @ aratana.com +1 ( 913 ).... Global headquarters in downtown Indianapolis spun off from Colorado State University provider of innovative solutions that protect enhance. Downtown Indianapolis undertakes no duty to update forward-looking statements to reflect events the... Your inbox to reflect events after the date of this release Announce Positive Opinion on GALLIPRANT® grapiprant. And CEO, called Aratana “ one of the most innovative start-ups in animal health. ” after date... No duty to update forward-looking statements to reflect events after the date of this release on market., https: //www.businesswire.com/news/home/20190718005410/en/ by PHOS Creative, elanco undertakes no duty to forward-looking!

Explora Magic Boots, Easy Definitions For Students, Ba Result 2020 Date, Fallout 76 Ultracite Weapon Mods, Chalk Pastel Drawings Easy, Pharmacy Assistant Course Singapore, Leek And Mushroom Risotto Jamie Oliver, Christmas Gift Ideas For Friends, Grappa Park City Menu, Peach Color Bridal Dresses Pakistani,

Leave a Reply

Your email address will not be published. Required fields are marked *